Clinical Trial: Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis
This study is currently recruiting patients.
OBJECTIVES: I. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in patients with cerebrotendinous xanthomatosis before and after a cholesterol- and cholestanol-free diet. II. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in these patients before and after lovastatin and chenodeoxycholic acid.
|Condition||Treatment or Intervention||Phase|
|Cerebrotendinous Xanthomatosis || Drug: chenodeoxycholic acid |
|Phase II |
MedlinePlus related topics: Genetic Disorders; Metabolic Disorders; Skin Diseases
Study Type: Interventional
Study Design: Treatment
Official Title: Effects of diet and medication in patients with cerebrotendinous xanthomatosis (CTX)
Expected Total Enrollment: 5
Study start: January 1996
PROTOCOL OUTLINE: Following a 2-week baseline assessment, patients participate in a feeding study for up to 3 weeks. The diet is free of cholesterol and cholestanol. For the next 4 weeks, patients return to their typical diet and are medicated with daily lovastatin and chenodeoxycholic acid. The feeding study is repeated for an additional 3 weeks, with the patient taking either lovastatin or chenodeoxycholic acid.
Genders Eligible for Study: Both
Location and Contact Information
Oregon Health Sciences University, Portland, Oregon, 97201-3098, United States; Recruiting
William Connor, Study Chair, Oregon Health and Science University
Record last reviewed: December 2003
Last Updated: October 13, 2004
Record first received: October 18, 1999
ClinicalTrials.gov Identifier: NCT00004346
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005